AI could personalize liver cancer care after surgery

NCT ID NCT07417800

Recruiting now Knowledge-focused Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aims to build an AI model that uses medical images and tissue samples to predict which liver cancer patients will benefit from additional treatments after surgery. Researchers will analyze data from 11,000 patients to see if the AI's recommendations match real-world outcomes. The goal is to help doctors tailor treatments to each patient, potentially reducing cancer recurrence.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this AI model could help doctors choose the best post-surgery treatment for liver cancer patients, potentially reducing recurrence and improving survival.
What could go wrong: This is an observational study, so the AI predictions are not yet used in real treatment decisions. The model may not perform as well in practice, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADJUVANT CHEMORADIOTHERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADJUVANT CHEMORADIOTHERAPY ARTIFICIAL INTELLIGENT HEPATOCELLULAR CARCINOMA (HCC) LENVATINIB LIVER SURGERY TACE

Contacts and locations

Locations

the Second Affiliated Hospital Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.